The TM domain of receptor tyrosine kinase (RTK) as ErbB family proteins (associated with several cancers) or other receptors as Neuropilin and G-protein coupled receptors (GPCRs) has been described these last years as putative targets to inhibit their dimerization/activation using several strategies. Here, NTRK1 is linked to cancer.